{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:26:44Z","timestamp":1791077204921,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.eururo.2011.11.009","type":"journal-article","created":{"date-parts":[[2011,11,14]],"date-time":"2011-11-14T02:35:31Z","timestamp":1321238131000},"page":"549-559","source":"Crossref","is-referenced-by-count":153,"title":["Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"61","author":[{"given":"Andrew J.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario A.","family":"Eisenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Nanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.11.009_bib0005","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2011.11.009_bib0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2011.11.009_bib0015","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2011.11.009_bib0020","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2011.11.009_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(11)70100-9","article-title":"Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract 1LBA]","volume":"47","author":"Parker","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2011.11.009_bib0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/pcan.2011.23","article-title":"Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer","volume":"14","author":"Antonarakis","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2011.11.009_bib0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/pcan.2011.24","article-title":"Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer","volume":"14","author":"Antonarakis","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2011.11.009_bib0040","doi-asserted-by":"crossref","unstructured":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 2001;69:89-95.","DOI":"10.1067\/mcp.2001.113989"},{"key":"10.1016\/j.eururo.2011.11.009_bib0045","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1158\/1078-0432.CCR-09-2167","article-title":"Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents","volume":"16","author":"Dancey","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2011.11.009_bib0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.eururo.2011.11.009_bib0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"key":"10.1016\/j.eururo.2011.11.009_bib0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/sim.4780110204","article-title":"Statistical validation of intermediate endpoints for chronic diseases","volume":"11","author":"Freedman","year":"1992","journal-title":"Stat Med"},{"key":"10.1016\/j.eururo.2011.11.009_bib0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrclinonc.2010.43","article-title":"Biomarkers and surrogate end points\u2014the challenge of statistical validation","volume":"7","author":"Buyse","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0075","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0080","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2011.35.8648","article-title":"End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0085","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1989::AID-CNCR15>3.0.CO;2-V","article-title":"The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate","volume":"83","author":"Vollmer","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.11.009_bib0090","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0095","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","article-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer","volume":"21","author":"Halabi","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0100","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/annonc\/mdm332","article-title":"Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients","volume":"18","author":"Oudard","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0105","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0110","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djj129","article-title":"Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16","volume":"98","author":"Petrylak","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2011.11.009_bib0115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/91.3.244","article-title":"Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer","volume":"91","author":"Scher","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2011.11.009_bib0120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","article-title":"Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0125","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO.2008.18.9159","article-title":"Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer","volume":"27","author":"Halabi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0130","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0135","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2004.07.099","article-title":"Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group","volume":"22","author":"Scher","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0140","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-06-1885","article-title":"The association between measures of progression and survival in castrate-metastatic prostate cancer","volume":"13","author":"Scher","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0145","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0150","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/cncr.25762","article-title":"Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer","volume":"117","author":"Smith","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.11.009_bib0155","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/pros.20627","article-title":"Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria","volume":"67","author":"Banu","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2011.11.009_bib0160","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.20493","article-title":"Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and\/or radiation therapy","volume":"101","author":"Smith","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.11.009_bib0165","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","article-title":"Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer","volume":"71","author":"Darshan","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0170","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/1078-0432.CCR-07-0944","article-title":"Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study","volume":"14","author":"Berthold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0175","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/annonc\/mdn062","article-title":"The postchemotherapy PSA surge syndrome","volume":"19","author":"Thuret","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0180","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eururo.2005.03.017","article-title":"Changes in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patients","volume":"48","author":"Sasaki","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0185","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/cncr.22971","article-title":"Treatment outcomes of small cell carcinoma of the prostate: a single-center study","volume":"110","author":"Spiess","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.11.009_bib0190","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.urology.2005.03.040","article-title":"Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study","volume":"66","author":"Taplin","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.11.009_bib0195","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1093\/annonc\/mdr004","article-title":"Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial","volume":"22","author":"Flechon","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0200","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0205","first-page":"146","article-title":"A case of cancer in which cells similar to those in the tumors were seen in the blood after death [abstract]","volume":"14","author":"Ashworth","year":"1869","journal-title":"Aust Med J"},{"key":"10.1016\/j.eururo.2011.11.009_bib0210","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0215","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1002\/cncr.25982","article-title":"The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy","volume":"117","author":"Sonpavde","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.11.009_bib0220","first-page":"LBA4517","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.eururo.2011.11.009_bib0225","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0002-9440(10)64451-3","article-title":"Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens","volume":"161","author":"Dash","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0230","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1158\/1078-0432.CCR-08-2036","article-title":"Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer","volume":"15","author":"Leversha","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0235","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1078-0432.CCR-06-2701","article-title":"Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer","volume":"13","author":"Shaffer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0240","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","article-title":"Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0245","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1158\/1541-7786.MCR-10-0490","article-title":"Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers","volume":"9","author":"Armstrong","year":"2011","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0250","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10549-011-1373-x","article-title":"Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients","volume":"130","author":"Raimondi","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.eururo.2011.11.009_bib0255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jnci\/djn419","article-title":"Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells","volume":"101","author":"Sieuwerts","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2011.11.009_bib0260","doi-asserted-by":"crossref","first-page":"18392","DOI":"10.1073\/pnas.1012539107","article-title":"Isolation of circulating tumor cells using a microvortex-generating herringbone-chip","volume":"107","author":"Stott","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2011.11.009_bib0265","doi-asserted-by":"crossref","first-page":"25re23","DOI":"10.1126\/scitranslmed.3000403","article-title":"Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer [abstract]","volume":"2","author":"Stott","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2011.11.009_bib0270","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1158\/1078-0432.CCR-10-2650","article-title":"Circulating tumor cells as biomarkers in prostate cancer","volume":"17","author":"Danila","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semcdb.2009.11.016","article-title":"Tumor-stroma co-evolution in prostate cancer progression and metastasis","volume":"21","author":"Josson","year":"2010","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0280","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/1078-0432.CCR-10-2523","article-title":"Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells","volume":"17","author":"Zhau","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0285","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-10-3120","article-title":"Characterization of bone metastases from rapid autopsies of prostate cancer patients","volume":"17","author":"Mehra","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0290","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1158\/0008-5472.CAN-04-2442","article-title":"Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program","volume":"64","author":"Shah","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0295","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2011.11.009_bib0300","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0305","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0009-9120(97)00113-6","article-title":"Biochemical markers of bone metabolism: an overview","volume":"30","author":"Christenson","year":"1997","journal-title":"Clin Biochem"},{"key":"10.1016\/j.eururo.2011.11.009_bib0310","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ijc.20314","article-title":"Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications","volume":"111","author":"Jung","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2011.11.009_bib0315","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.eururo.2010.12.006","article-title":"Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid","volume":"59","author":"Jung","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0320","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/1097-0142(197908)44:2<763::AID-CNCR2820440251>3.0.CO;2-5","article-title":"Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate","volume":"44","author":"Berry","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.11.009_bib0325","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0330","doi-asserted-by":"crossref","unstructured":"Sonpavde G, Pond GR, Berry WR, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. In press.","DOI":"10.1016\/j.urolonc.2010.07.002"},{"key":"10.1016\/j.eururo.2011.11.009_bib0335","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0340","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.11.009_bib0345","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.eururo.2011.11.009_bib0350","unstructured":"Halabi S, Ou S, Vogelzang NJ, Kantoff PW, Scher HI, Small EJ. The prognostic value of change in hemoglobin (HGB), LDH and PSA levels at 3 months from baseline in men with castrate recurrent prostate cancer [abstract]. At: American Society of Clinical Oncology Prostate Cancer Symposium; February 22-24, 2007; Orlando, FL, USA. http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=46&abstractID=20305."},{"key":"10.1016\/j.eururo.2011.11.009_bib0355","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2002.11.021","article-title":"Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration","volume":"20","author":"Smaletz","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0360","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","article-title":"Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer","volume":"16","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0365","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejca.2009.11.007","article-title":"The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival","volume":"46","author":"Armstrong","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2011.11.009_bib0370","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","volume":"17","author":"Ryan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0375","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1200\/jco.2011.29.15_suppl.4516","article-title":"Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial","volume":"29","author":"Hussain","year":"2011","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.eururo.2011.11.009_bib0380","doi-asserted-by":"crossref","first-page":"LBA4511","DOI":"10.1200\/jco.2010.28.18_suppl.lba4511","article-title":"A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401","volume":"28","author":"Kelly","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.eururo.2011.11.009_bib0385","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/jco.2011.29.15_suppl.4515","article-title":"Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC)","volume":"29","author":"Ou","year":"2011","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.eururo.2011.11.009_bib0390","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0395","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1158\/1078-0432.CCR-04-0496","article-title":"Evaluating the efficiency of targeted designs for randomized clinical trials","volume":"10","author":"Simon","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.11.009_bib0400","unstructured":"Memorandum of understanding between the FDA, NCI, and CMS for the FDA\/NCI\/CMS Oncology Biomarker Qualification Initiative [document MOU 225-06-8001]. US Food and Drug Administration Web site. http:\/\/www.fda.gov\/AboutFDA\/PartnershipsCollaborations\/MemorandaofUnderstandingMOUs\/DomesticMOUs\/ucm115681.htm."},{"key":"10.1016\/j.eururo.2011.11.009_bib0405","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.clpt.6100471","article-title":"The Biomarkers Consortium: on the critical path of drug discovery","volume":"83","author":"Altar","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eururo.2011.11.009_bib0410","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2007.15.0367","article-title":"Pain predicts overall survival in men with metastatic castration-refractory prostate cancer","volume":"26","author":"Halabi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.11.009_bib0415","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1158\/1078-0432.CCR-05-0109","article-title":"Prostate cancer clinical trial end points: \u201cRECIST\u201ding a step backwards","volume":"11","author":"Scher","year":"2005","journal-title":"Clin Cancer Res"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811012425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811012425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T10:56:45Z","timestamp":1543402605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811012425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0302283811012425"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.11.009","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}